High impact
Prostate Cancer Screening (CPB 0521, reviewed 2025-11-25)
Aetna·Effective Nov 25, 2025
Aetna's updated Prostate Cancer Screening policy (CPB 0521) clarifies coverage for PSA screening and digital rectal examinations while establishing a comprehensive list of experimental/unproven tests that are NOT covered. The policy maintains coverage for standard PSA testing (CPT 84152, 84153, 84154) and DRE (G0102, G0103) for eligible age groups, but explicitly excludes 25+ alternative screening tests including PCA3, four-kallikrein panel, Stockholm3, and genetic-based screening tests. Billing teams must immediately stop submitting claims for the listed experimental codes and ensure claims use only the covered CPT/HCPCS codes when medical necessity criteria are met.